Meeting
2022 ASCO Annual Meeting
Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.
Presenter
Susan N. Chi, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02601937
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10040)
DOI
10.1200/JCO.2022.40.16_suppl.10040
Abstract #
10040
Poster Bd #
255
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2015 ASCO Annual Meeting
Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).
Speaker: Mark W. Kieran, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
Speaker: Justin M. Watts, MD
Videos & Slides
2024 ASCO Annual Meeting
Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.
Speaker: Biao Zheng, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.
Speaker: Vishu Avutu, MD